Study S000360

A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial

ClinicalTrials.gov record

Registration

Registration: NCT07357415
Acronym: TRIUMPH-9
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 600
Start: 2026-01-24
Primary completion: 2028-10
Lead sponsor: Eli Lilly and Company
Conditions: Obesity; Overweight
Interventions: DRUG:Retatrutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:J1I-MC-GZQL

Registered primary outcomes

Percent Change from Baseline in Body Weight [Baseline, Week 104]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.